THE COST-EFFECTIVENESS OF HIV TESTING OF PHYSICIANS AND DENTISTS IN THE UNITED-STATES

被引:28
|
作者
PHILLIPS, KA
LOWE, RA
KAHN, JG
LURIE, P
AVINS, AL
CICCARONE, D
机构
[1] UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143
[2] UNIV CALIF SAN FRANCISCO,SCH MED,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143
[3] UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DIV GEN INTERNAL MED,SAN FRANCISCO,CA
[4] UNIV CALIF BERKELEY,CTR STUDENT HLTH,BERKELEY,CA
来源
关键词
D O I
10.1001/jama.271.11.851
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective.-To evaluate the cost-effectiveness of alternative policies for human immunodeficiency testing (HIV) testing of physicians and dentists. Methods.-Decision analysis and cost-effectiveness analysis from a societal perspective were used. Data were derived from extensive literature review and consultation with experts. We conducted sensitivity analyses and also performed a cost-benefit analysis. Analyses.-We analyzed policies for mandatory or voluntary testing of all physicians, surgeons, and dentists; for those testing positive, we analyzed mandatory or voluntary exclusion from practice, restriction from performance of invasive procedures, or requirements to inform patients of serostatus. Main Outcome Measure.-Cost per patient infection averted. Results.-Although one-time mandatory testing of surgeons and dentists with mandatory restriction of those found to be HIV-positive is more cost-effective than other policies, the cost-effectiveness varies tremendously under different scenarios. Results were highly sensitive to several data inputs, especially HIV seroprevalence of surgeons and dentists and transmission risk. For example, under a medium seroprevalence and transmission risk scenario, mandatory testing of all surgeons might avert 25 infections at a total cost of $27.9 million or $1 115 000 per infection averted and an incremental cost of $291 000 compared with current testing; however, the incremental cost-effectiveness per patient infection averted ranges from $29 807 000 under a low-risk scenario to a savings of $81 000 under a high-risk scenario. Conclusion.-Our analysis neither justifies nor precludes a mandatory testing policy. Further research on the key data inputs is needed. Given the ethical, social, and public health implications, mandatory testing policies should not be implemented without greater certainty as to their cost-effectiveness.
引用
收藏
页码:851 / 858
页数:8
相关论文
共 50 条
  • [31] Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States
    Bernard, Cora L.
    Brandeau, Margaret L.
    Humphreys, Keith
    Bendavid, Eran
    Holodniy, Mark
    Weyant, Christopher
    Owens, Douglas K.
    Goldhaber-Fiebert, Jeremy D.
    ANNALS OF INTERNAL MEDICINE, 2016, 165 (01) : 10 - +
  • [32] The Cost-Effectiveness and Population Outcomes of Expanded HIV Screening and Antiretroviral Treatment in the United States
    Long, Elisa F.
    Brandeau, Margaret L.
    Owens, Douglas K.
    ANNALS OF INTERNAL MEDICINE, 2010, 153 (12) : 778 - +
  • [33] THE HIV TESTING POLICIES OF UNITED-STATES HOSPITALS
    HENRY, K
    CAMPBELL, S
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (13): : 1685 - 1685
  • [34] Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany
    Vijayaraghavan, Arthi
    Efrusy, Molly B.
    Goeke, Burkhard
    Kirchner, Thomas
    Santas, Christopher C.
    Goldberg, Richard M.
    INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (02) : 438 - 445
  • [35] Cost-effectiveness of cascade genetic testing for familial hypercholesterolemia in the United States: A simulation analysis
    Jackson, Candace L.
    Huschka, Todd
    Borah, Bijan
    Agre, Katherine
    Zordok, Magdi
    Farwati, Medhat
    Moriarty, James
    Kullo, Iftikhar J.
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 8
  • [36] Serologic Testing for Syphilis in the United States: A Cost-Effectiveness Analysis of Two Screening Algorithms
    Owusu-Edusei, Kwame, Jr.
    Peterman, Thomas A.
    Ballard, Ronald C.
    SEXUALLY TRANSMITTED DISEASES, 2011, 38 (01) : 1 - 7
  • [37] UNITED-STATES PHYSICIANS
    不详
    LANCET, 1980, 1 (8178): : 1152 - 1152
  • [38] Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States
    Holtgrave, DR
    Pinkerton, SD
    Jones, TS
    Lurie, P
    Vlahov, D
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1998, 18 : S133 - S138
  • [39] Cost-effectiveness estimates for antenatal HIV testing in the Netherlands
    Rozenbaum, M. H.
    Verweel, G.
    Folkerts, D. K. F.
    Dronkers, F.
    van den Hoek, J. A. R.
    Hartwig, N. G.
    de Groot, R.
    Postma, M. J.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2008, 19 (10) : 668 - 675
  • [40] Cost-effectiveness of HIV counseling and testing in US prisons
    Varghese, B
    Peterman, TA
    JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 2001, 78 (02): : 304 - 312